Massachusetts Institute of Technology

Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

Retrieved on: 
Monday, March 25, 2024
Mechanical, SAS, American Heart Association, Percutaneous aortic valve replacement, Product marketing, Abbott Laboratories, Massachusetts Institute of Technology, Business, Patient, Business development, LAA, Medtronic, MD, Senior, Master, Retirement, TAVR, Marketing, Management

Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).

Key Points: 
  • Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer (CEO).
  • In conjunction with this, and following eight years at the helm of the business, Helmut Straubinger is retiring as President & CEO.
  • Ahmed Elmouelhi is a seasoned professional with more than 20 years of medical device experience across strategy, sales and marketing, R&D, and clinical science.
  • Before joining TRiCares, Ahmed served as the Senior Vice President of Product Marketing, Strategy, and Business Development at AtriCure.

Repligen Appoints Maggie A. Pax to Board of Directors

Retrieved on: 
Tuesday, March 19, 2024
College, Innovation, Growth, Life Technologies, Repligen, Business, MIT, Thermo Fisher Scientific, Harvard Business School, Strategic planning, Business development, Acquisition, Massachusetts Institute of Technology, MBA, Marketing, Holy Cross, Alimera Sciences, Corporation, Management

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.
  • Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies.
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We’re very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in the life sciences industry.
  • Hunt, Chief Executive Officer for Repligen said, “Maggie understands first-hand the drivers of growth for our industry and has touched many of the focus areas for Repligen: key account programs, continuous innovation and M&A integration.

F5 Welcomes Lyra Schramm as Chief People Officer and Kunal Anand as Chief Technology Officer

Retrieved on: 
Tuesday, April 2, 2024
Software, Technology, Data Management, Security, Culture, Organization, Innovation, Growth, CPO, Imperva, CISO, FFIV, AI, Life, AWS, Massachusetts Institute of Technology, BBC Worldwide, API, Workplace, Melinda French Gates, Management

F5, Inc. (NASDAQ: FFIV) today announced the appointment of Lyra Schramm as Executive Vice President and Chief People Officer (CPO) and Kunal Anand as Executive Vice President and Chief Technology Officer (CTO).

Key Points: 
  • F5, Inc. (NASDAQ: FFIV) today announced the appointment of Lyra Schramm as Executive Vice President and Chief People Officer (CPO) and Kunal Anand as Executive Vice President and Chief Technology Officer (CTO).
  • Schramm and Anand join F5’s executive leadership team reporting to President and CEO, François Locoh-Donou.
  • "Lyra and Kunal not only bring business acumen and fresh perspectives that will raise the bar for F5, but they are also humble, generous, and authentic leaders who embody our culture of excellence,” said Locoh-Donou.
  • Most recently, Anand held the dual roles of CTO and Chief Information Security Officer (CISO) at Imperva.

Moving iMage Technologies (MiT) Announces Stock Repurchase Program and 10b5-1 Stock Trading Plan

Retrieved on: 
Monday, April 1, 2024
Entertainment, Technology, TV and Radio, Film & Motion Pictures, Audio, Video, Hardware, Broker-dealer, Share repurchase, Policy, Rule, Massachusetts Institute of Technology

Moving iMage Technologies (NYSE American: MITQ) (“MiT”), a leading technology and services company for cinema, Esports, stadiums, arenas and other out-of-home entertainment venues, today announced it has adopted a new share repurchase program to replace the Company’s previous $1.0 million share repurchase program that expired on March 23, 2024.

Key Points: 
  • Moving iMage Technologies (NYSE American: MITQ) (“MiT”), a leading technology and services company for cinema, Esports, stadiums, arenas and other out-of-home entertainment venues, today announced it has adopted a new share repurchase program to replace the Company’s previous $1.0 million share repurchase program that expired on March 23, 2024.
  • The new share repurchase program authorizes the repurchase of up to $363,000 worth of shares and will expire at the earlier of June 30, 2024, or when the maximum dollar amount of shares is repurchased.
  • Through March 22, 2024, under the prior repurchase plan, the Company repurchased approximately 6.3% of the total shares outstanding for $637,000.
  • An independent U.S. broker-dealer is acting as the Company’s agent to purchase its shares on pre-arranged terms pursuant to the Rule 10b5-1 stock trading plan.

Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Harvard Medical School, Flexner Report, Organization, Bone marrow, Internal medicine, UCSF, Hematology, Science, HST, Massachusetts Institute of Technology, BCMA, Patient, HIV, Dartmouth College, BMS, Cancer, Bristol Myers Squibb, Doctor of Philosophy, Daratumumab, Biochemistry, Chemistry, Therapy, Harvard University, Hospital, Johnson & Johnson, Drug development, FDA, Pharmaceutical industry

Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.

Key Points: 
  • Kelonia Therapeutics , a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors.
  • Furthermore, some patients never receive their autologous CAR-T products due to disease progression or clinical deterioration during the manufacturing window.
  • In addition, the field of cell and gene therapy has gained tremendous expertise and insight into the manufacturing of lentiviral vectors at commercial scale.
  • from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

Biswas Family Foundation, Milken Institute Announce $15 Million in Funding for Research at the Intersection of AI and Health

Retrieved on: 
Tuesday, March 12, 2024
Technology, General Health, Infectious Diseases, Foundation, Philanthropy, Science, Biotechnology, Health, Health Technology, Other Philanthropy, Other Science, Research, Other Technology, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, Gladstone Institutes, Diagnosis, Health informatics, Harvard Medical School, Computational biology, SPARC, Transformative use, Test management, Computer science, Data science, Disease, Assistant, Massachusetts Institute of Technology, Associate, Chatbot, Partnership, Genetics, Patient, Common, Artificial intelligence, AI, Doctor of Philosophy, Interpretation, Investment, Stanford University, Milken Institute, Genetic distance, Medical device

The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .

Key Points: 
  • The Biswas Family Foundation , in partnership with the Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC) , is pleased to announce the inaugural recipients of the Transformative Computational Biology Grant Program .
  • Five multidisciplinary research teams will receive nearly $14 million total in grant funding for projects aiming to drive translational impact and the advancement of artificial intelligence (AI) models in clinical settings for diagnosis and treatment.
  • Additional support to enhance AI and computational biology research, inclusive of a gift to the Arc Institute , marks a total of $15 million in giving for the Biswas Family Foundation for this interdisciplinary field, and the beginning of more support.
  • To learn more about the Transformative Computational Biology Grant Program and to read the Giving Smarter Guide, visit: https://bit.ly/3Vae8Kq .

Settlement Administrator Angeion Group Announces Proposed Settlements with Brown University, University of Chicago, the Trustees of Columbia University in the City of New York, Trustees of Dartmouth College, Duke University, Emory University, Northwestern

Retrieved on: 
Friday, March 29, 2024
Vanderbilt University, Tax, University, Action, Hearing, Summons, City, Emory University, University of Chicago, Class, Dartmouth College, Brown University, Fairness, Info, Massachusetts Institute of Technology, District court, Cornell University, Georgetown University, Defendant, Student, Rice, Settlement, Claim, California Institute of Technology, PC, University of Pennsylvania, Plaintiff, Trustee, School, University of Notre Dame, Columbia University, Johns Hopkins University, Pharmaceutical industry

PHILADELPHIA, March 29, 2024 /PRNewswire/ -- A federal court has preliminarily approved proposed settlements ("Settlements") with the following ten defendant universities: Brown University ("Brown"), University of Chicago ("Chicago"), the Trustees of Columbia University in the City of New York ("Columbia"), Trustees of Dartmouth College ("Dartmouth"), Duke University ("Duke"), Emory University ("Emory"), Northwestern University ("Northwestern"), William Marsh Rice University ("Rice"), Vanderbilt University ("Vanderbilt") and Yale University ("Yale"). The Court has also preliminarily approved a Settlement Class of students who attended the following seventeen schools (during certain time periods): Brown, California Institute of Technology, Chicago, Columbia, Cornell University, Dartmouth, Duke, Emory, Georgetown University, Johns Hopkins University, Massachusetts Institute of Technology, Northwestern, University of Notre Dame, University of Pennsylvania, Rice, Vanderbilt, and Yale (the "Defendants," or "Universities," or "Defendant Universities"). As a part of the Settlement, the Defendant Universities have agreed to make a settlement payment of $284 million and to provide certain additional information to Plaintiffs in this antitrust class action lawsuit called Henry, et al. v. Brown University, et al., 1:22-cv-00125, pending in the United States District Court for the Northern District of Illinois ("Action").

Key Points: 
  • PHILADELPHIA, March 29, 2024 /PRNewswire/ -- A federal court has preliminarily approved proposed settlements ("Settlements") with the following ten defendant universities: Brown University ("Brown"), University of Chicago ("Chicago"), the Trustees of Columbia University in the City of New York ("Columbia"), Trustees of Dartmouth College ("Dartmouth"), Duke University ("Duke"), Emory University ("Emory"), Northwestern University ("Northwestern"), William Marsh Rice University ("Rice"), Vanderbilt University ("Vanderbilt") and Yale University ("Yale").
  • v. Brown University, et al., 1:22-cv-00125, pending in the United States District Court for the Northern District of Illinois ("Action").
  • The Action was brought by certain students who attended the Universities while receiving partial need-based financial aid.
  • The Action alleges that the Universities conspired in violation of the federal antitrust laws regarding principles, formulas, and methods of determining financial aid.

OKX Web3 University Tour Champions The Next Generation of Builders and Innovators

Retrieved on: 
Friday, March 22, 2024
Massachusetts Institute of Technology, SAN, Duke University, Internet, Columbia University, University of Washington, University, Faculty, OKX, Student, Harvard University, Stanford University, UCLA, University of California, Berkeley, Cryptocurrency

SAN JOSE, Calif., March 22, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, has successfully launched its OKX Web3 University tour, engaging with top students and faculty about the future of Web3 technology.

Key Points: 
  • SAN JOSE, Calif., March 22, 2024 /PRNewswire/ -- OKX , a leading global Web3 technology company and crypto exchange, has successfully launched its OKX Web3 University tour, engaging with top students and faculty about the future of Web3 technology.
  • The tour has already held events at Stanford University, UC Berkeley, UCLA, and the University of Southern California.
  • The OKX Web3 team participated in fireside chats and panel discussions at each university dedicated to decentralization, blockchain infrastructure, and the builder community.
  • The OKX university tour will continue to make stops at leading technology campuses across the U.S. over the next month.

Loreli Cadapan Joins Liquibase as Vice President of Product

Retrieved on: 
Tuesday, March 19, 2024
Database, Computer science, Massachusetts Institute of Technology, Partnership, MIT, DevOps, Artificial intelligence, Software, Bachelor, Woman, STEM, Oracle, Stanford University, ActiveState, Management

AUSTIN, Texas, March 19, 2024 /PRNewswire/ -- Leading database change management solution Liquibase announces the appointment of Loreli Cadapan as Vice President of Product. The MIT alum and ex-Oracle Director of DevOps unites her expertise in leading and building DevOps teams and products as she charts a user-centric roadmap expanding the uses, capabilities, and values of database CI/CD. Building on Liquibase's open-source foundation and core automation, governance, and observability features, Cadapan strives to bring DevOps integration to all of the world's data stores.

Key Points: 
  • AUSTIN, Texas, March 19, 2024 /PRNewswire/ -- Leading database change management solution Liquibase announces the appointment of Loreli Cadapan as Vice President of Product .
  • "As a DevOps devotee and longtime Liquibase user, I know how game-changing it is to extend DevOps to the database," says Cadapan.
  • In 2017, Cadapan kicked off a five-year stint at DevOps/DevSecOps platform JFrog as Sr. Director of Product, building the U.S. product team from the ground up.
  • Prior to joining Liquibase in December 2023, she spent two years as Chief Product Officer at ActiveState with its enterprise DevSecOps platform for software supply chain security.

Sandoz announces nominations to the Board of Directors and leadership change

Retrieved on: 
Tuesday, March 5, 2024
Remco, J&J, Person, Chemistry, Mechanical, Growth, IMD, Swisscom, University, Lufthansa, Organization, 10x Genomics, Annual general meeting, Erasmus University Rotterdam, Johnson & Johnson, MBA, Gesellschaft mit beschränkter Haftung, Genomics, Retirement, Flexner Report, Harvard Medical School, HST, CFO, Massachusetts Institute of Technology, Merck, Harvard University, Executive Committee, Doctor of Philosophy, Annual, KPMG, Management

Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.

Key Points: 
  • Gilbert Ghostine, Sandoz Chairman, said: "Our company evolves, and so does our leadership team.
  • I am pleased we can propose exceptional people in science and in business for election to the Board of Directors this year.
  • The new Board talent maintains the complementarity of expertise and experience in the areas relevant to Sandoz.
  • The following persons are recommended for election to the Board of Directors at the Annual General Meeting on April 30, 2024: